The Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID) was established by the Department of Medicine to support both fundamental and translational research on human disease.
It houses up to 250 scientists working within 25 research groups. Our work focusses on understanding the pathogenesis and improving the management of immune-related disorders and transforming our understanding of how the infectious agents interact with humans.
CITIID transforms immunity and infection research in Cambridge by providing researchers with advanced facilities that are in close proximity and enable them to optimise their work on human immune, inflammatory and infectious diseases. By bringing together its clinical capabilities and key industry partners, CITIID is also well-placed to drive therapeutic breakthroughs, improve patient outcomes and advance population health both in the UK and abroad.
- Likelihood of severe and ‘long’ COVID may be established very early on following infection -
- CITIID PhD in Infection and Immunity Programme Launched -
- Open-source toolkit helps developing countries meet demand for COVID-19 research and diagnostics -
- Cambridge-led SARS-CoV-2 genomic surveillance consortium receives £12.2 million -
- Age and pre-existing conditions increase risk of stroke among COVID-19 patients -
- CITIID – Taking on COVID for the long haul -
- Professor Ravi Gupta named as one of Time Magazine’s 100 Most Influential People of the Year -
- Professor Ravi Gupta: People who change the world -
- COVID Six Months On – BBC and Prof Ravi Gupta -
- Combining PCR and antibody tests at point of care dramatically increases COVID-19 detection in hospitalised patients -